期刊文献+

反相高效液相色谱法测定雷替曲塞的含量和有关物质 被引量:6

RP-HPLC Determination of Content and Related Substances of Raltitrexed
下载PDF
导出
摘要 目的:建立测定雷替曲塞含量及其有关物质的反相高效液相色谱法。方法:采用 Diamonsil C_(18)(150mm×4.6mm,5μm)色谱柱,以缓冲液(0.03mol·L^(-1)磷酸氢二钾,0.03 mol·L^(-1)三乙胺,磷酸调 pH 为7.2)-甲醇(69:31)为流动相,检测波长为342 nm,柱温35℃,流速0.9 mL·min^(-1),按峰面积外标法计算。结果:雷替曲塞在1.0~100.0μg·mL^(-1)范围内呈良好线性,方法回收率为99.94%~102.16%(n=5),日内、日间 RSD<2.22%(n=5),雷替曲塞含量在99.38%~100.45%之间,有关物质<0.58%。结论:本方法简便,快速,结果准确,可靠,重现性好,所测该药含量及有关物质均在合格范围之内。 Objective :To establish HPLC method for the determination of content and related substance of rahitrexed. Method:A Diamonsil C is (150mm×4.6mm,5μm)column was used. The mobile phase was composed of buffer(0. 03 mol· L^- 1 K2 HPO4 _ 0. 03 mol· L^- 1 ( CH3 CH2 ) 3 N, pH = 7. 2 ) - CH3 OH ( 69 : 31 ). Detection wavelength was 342 nm. Flow rate was 0. 9 mL· min^- 1. The temperature of the column was 35℃. Results :The linearity of the calibration curve was well correlated( r = 0. 9997)within the range of 1.0 -100. 0μg·mL^-1. The recovery was 99.94% - 102. 16%. The within and between day RSD were less than 2. 22%. The content of related substances were less than 0.58%. Conclusion : The method is simple, rapid, results are accurate and good reproducible. The content and related substance of rahitrexed are both within acceptable range.
出处 《药物分析杂志》 CAS CSCD 北大核心 2005年第9期1046-1048,共3页 Chinese Journal of Pharmaceutical Analysis
  • 相关文献

参考文献9

  • 1Jodrell DI. Newell DR. Gibson W, et al. The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemoth Pharm, 1991,28 (5) :331.
  • 2Van Cutsem E, Cunningham D, Maroun J, et al. Raltitrexed: current clinical status and future directions. Ann Onco1,2002,13 (4) :513.
  • 3Clarke SJ, Beale PJ, Rivory LP. Clinical and preclinical pharmacokinetics of raltitrexed. Clin Pharmacokinet ,2000,39 (6) :429.
  • 4Raats J,Rapoport B,Mahomed R,et al. A phase I clinical trial of cisplatin and raltitrexed in newly diagnosed patients with metastatic carcinoma of unknown primary(CUP). Ann Oncol,2000 ,11:625.
  • 5Armand JP, Seymour L, Evans TRJ. Raltitrexed [ Tomudex ( TM ) ] in combination with platinum- based agents and/or anthracyclines: Preliminary results of phase I clinical trials. Eur J Cancer, 1999,35 :S14.
  • 6Gibson W, Bisset GM, Marsham PR ,et al. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694 ,in mouse and human cultured cells. Biochem Pharmacol, 1993,45 (4):863.
  • 7Masi G,Falcone A,Di Paola A,et al. A phase I and pharmacokinetic study of irinotecan given as a 7 - day continuous infusion in metastatic colorectal cancer patients pretreated with 5 - fluorouracil or raltitrexed. Clin Cancer Res ,2004,10(5 ) : 1657.
  • 8Ford HER, Mitchell F, CunninghamD, et al, Patterns of elevation of plasma 2' - deoxyuridine, a surrogate marker of thymidylate synthase(TS)inhibition,after administration of two different schedules of 5 -fluorouracil and the specific TS inhibitors raltitrexed ( Tomudex ) and ZD9331. Clin Cancer Res ,201Y2,8 ( 1 ) :103.
  • 9Aheme GW, Ward E, Lawrence N, et al. Comparison of plasma and tissue levels of ZD1694 ( Tomudex ) , a highly polyglutamatable quinazoline thymidylate synrthase inhibitor, in precl/nical models. Brit J Cancer,1998,77 (2) :221.

同被引文献2141

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部